SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS
申请人:High Point Pharmaceuticals, LLC
公开号:EP1421071B1
公开(公告)日:2009-11-18
US7208497B2
申请人:——
公开号:US7208497B2
公开(公告)日:2007-04-24
[EN] SUBSTITUTED PIPERAZINES AND DIAZEPANES<br/>[FR] PIPERAZINES ET DIAZEPANES SUBSTITUES
申请人:NOVO NORDISK AS
公开号:WO2003004480A2
公开(公告)日:2003-01-16
A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
[EN] NEW COMPOUNDS I<br/>[FR] COMPOSÉS INÉDITS I
申请人:BIOVITRUM AB PUBL
公开号:WO2010031789A1
公开(公告)日:2010-03-25
The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.